Oklo Inc.’s (NYSE: OKLO) ambitions in nuclear-powered cancer treatment took a concrete step forward after federal regulators cleared the company’s Groves-1 reactor for unrestricted operations.
The U.S. Department of Energy lifted the final operational hold point on the Groves Isotope Test Reactor, allowing Oklo to transition the facility from a demonstration asset into a full research and testing platform.
The clearance sets the stage for Oklo’s next major project, Groves-2 Forge, a planned pilot facility selected under the DOE’s Nuclear Energy Launch Pad initiative that would integrate multiple stages of isotope production under one roof.
Groves-2 Forge is designed to combine reactor irradiation with hot-cell processing, encompassing isotope separation, product recovery, packaging and transportation, with lutetium-177 as its initial target isotope.
Lutetium-177 is used in targeted cancer therapies, positioning Oklo at an intersection of advanced nuclear technology and pharmaceutical-grade isotope supply chains.
The foundation for those ambitions rests on what Groves-1 already accomplished: achieving first criticality in August 2026 under the DOE’s Reactor Pilot Program, becoming the first facility under that program to hit the milestone on private land.
Perhaps as notable as the milestone itself is the timeline, with Oklo bringing the reactor from a greenfield construction site to operational readiness in under twelve months.
With unrestricted operations now authorized, Groves-1 will serve as a proving ground for technologies and procedures intended to support both Oklo’s future isotope reactors and its Aurora fast fission powerhouses.
The testing regime already features unconventional methods, including the use of eye-tracking glasses during a recent reactor startup to map where operators directed their visual attention and pinpoint weaknesses in the human-machine interface.
Data gathered through those observations is expected to feed directly into refined reactor controls and improved design features for upcoming facilities, reflecting a hands-on approach to iterative engineering.
Equipment reliability evaluations are also underway, with particular attention focused on the performance of control rod drive mechanisms, a critical safety and operational component in any reactor system.
Criticality and reactivity benchmarking activities planned at the site could generate data with reach well beyond Oklo’s own projects, potentially improving fuel performance and power output across small and large light water reactors, including the existing commercial fleet.
On the investment side, Oklo currently carries a Zacks Rank of 3, or Hold, while sector peers Curtiss-Wright Corporation (NYSE: CW), GE Vernova Inc. (NYSE: GEV) and NexGen Energy Ltd. (NYSE: NXE) each hold a Rank of 2, or Buy.
Analysts project GE Vernova’s 2026 earnings will grow 79.5% year-over-year, while NexGen Energy’s consensus estimate points to 50% growth and Curtiss-Wright’s forecast indicates a 17.2% gain for the same period.
For Oklo, the broader significance of Groves-1’s progression lies in what it demonstrates about execution speed and technical capability as the company builds toward a larger pipeline of nuclear and isotope projects.
